125 related articles for article (PubMed ID: 26016790)
61. Trends in Adenoma Detection Rates During the First 10 Years of the German Screening Colonoscopy Program.
Brenner H; Altenhofen L; Kretschmann J; Rösch T; Pox C; Stock C; Hoffmeister M
Gastroenterology; 2015 Aug; 149(2):356-66.e1. PubMed ID: 25911510
[TBL] [Abstract][Full Text] [Related]
62. The 2003 Australian Breast Health Survey: survey design and preliminary results.
Villanueva EV; Jones S; Nehill C; Favelle S; Steel D; Iverson D; Zorbas H
BMC Public Health; 2008 Jan; 8():13. PubMed ID: 18194528
[TBL] [Abstract][Full Text] [Related]
63. Cancer screening: reaching the limits or terra incognita? Lessons from the EDIFICE surveys.
Eisinger F; Roussel C; Morère JF; Viguier J
Eur J Cancer Prev; 2011 Jan; 20 Suppl 1():S42-4. PubMed ID: 21245681
[TBL] [Abstract][Full Text] [Related]
64. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching.
Leuraud K; Jezewski-Serra D; Viguier J; Salines E
Cancer Epidemiol; 2013 Dec; 37(6):959-67. PubMed ID: 24035240
[TBL] [Abstract][Full Text] [Related]
65. People's willingness to accept overdetection in cancer screening: population survey.
Van den Bruel A; Jones C; Yang Y; Oke J; Hewitson P
BMJ; 2015 Mar; 350():h980. PubMed ID: 25736617
[TBL] [Abstract][Full Text] [Related]
66. Breast cancer screening effectiveness in Portugal central Region.
Bastos J; Rodrigues V; Paap E; Broeders M; Pina M; Cruz D; Carrito B; António Silva M
Eur J Cancer Prev; 2017 Sep; 26 Joining forces for better cancer registration in Europe():S204-S207. PubMed ID: 28574867
[TBL] [Abstract][Full Text] [Related]
67. Estimation of breast, prostate, and colorectal cancer incidence using a French administrative database (general sample of health insurance beneficiaries).
Doat S; Samson S; Fagot-Campagna A; Tuppin P; Menegaux F
Rev Epidemiol Sante Publique; 2016 Jun; 64(3):145-52. PubMed ID: 27238161
[TBL] [Abstract][Full Text] [Related]
68. Racial Disparities Vary by Patient Life Expectancy in Screening for Breast, Prostate, and Colorectal Cancers.
Schoenborn NL; Huang J; Boyd CM; Pollack CE
J Gen Intern Med; 2020 Nov; 35(11):3389-3391. PubMed ID: 31797159
[No Abstract] [Full Text] [Related]
69. Colorectal cancer screening in a Spanish population.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Parra-Blanco A; Jiménez A
Med Clin (Barc); 2009 Nov; 133(19):736-40. PubMed ID: 19892375
[TBL] [Abstract][Full Text] [Related]
70. The Big 3: An Updated Overview of Colorectal, Breast, and Prostate Cancers.
Gordon J; Fischer-Cartlidge E; Barton-Burke M
Nurs Clin North Am; 2017 Mar; 52(1):27-52. PubMed ID: 28189165
[TBL] [Abstract][Full Text] [Related]
71. Breast cancer screening programme participation and socioeconomic deprivation in France.
Deborde T; Chatignoux E; Quintin C; Beltzer N; Hamers FF; Rogel A
Prev Med; 2018 Oct; 115():53-60. PubMed ID: 30099047
[TBL] [Abstract][Full Text] [Related]
72. Low participation in organized colorectal cancer screening in France: underlying ethical issues.
Moutel G; Duchange N; Lièvre A; Orgerie MB; Jullian O; Sancho-Garnier H; Darquy S
Eur J Cancer Prev; 2019 Jan; 28(1):27-32. PubMed ID: 29176350
[TBL] [Abstract][Full Text] [Related]
73. Cancer screening: continuing instability.
Eisinger F
Eur J Cancer Prev; 2015 Jun; 24 Suppl():S65-7. PubMed ID: 26016789
[No Abstract] [Full Text] [Related]
74. Breast cancer and screening in persons with an intellectual disability living in institutions in France.
Trétarre B; Bourgarel S; Stoebner-Delbarre A; Jacot W; Bessaoud F; Satge D
J Intellect Disabil Res; 2017 Mar; 61(3):266-278. PubMed ID: 27624823
[TBL] [Abstract][Full Text] [Related]
75. Cancer screening in Korea, 2010: results from the Korean National Cancer Screening Survey.
Park B; Lee HY; Choi KS; Lee YY; Jun JK; Park EC
Asian Pac J Cancer Prev; 2011; 12(8):2123-8. PubMed ID: 22292663
[TBL] [Abstract][Full Text] [Related]
76. Implementation Science Workshop: Barriers and Facilitators to Increasing Mammography Screening Rates in California's Public Hospitals.
Clarity C; Gourley G; Lyles C; Ackerman S; Handley MA; Schillinger D; Sarkar U; Conigliaro J
J Gen Intern Med; 2017 Jun; 32(6):697-705. PubMed ID: 28188571
[No Abstract] [Full Text] [Related]
77. Future perspectives for cancer screening.
Viguier J
Eur J Cancer Prev; 2015 Jun; 24 Suppl():S87-9. PubMed ID: 26016794
[TBL] [Abstract][Full Text] [Related]
78. Prevalence of colorectal cancer and breast cancer screening according to history of diabetes in 2010-2019.
Liu Z; Song M
J Med Screen; 2023 Sep; 30(3):156-158. PubMed ID: 37259533
[TBL] [Abstract][Full Text] [Related]
79. Effects of communicating lifetime risks and screening rates of colorectal cancer and breast cancer.
Liu J; Niederdeppe J
Risk Anal; 2023 Dec; 43(12):2581-2596. PubMed ID: 36810789
[TBL] [Abstract][Full Text] [Related]
80. Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures.
Tau A; Bernica J; Thrift AP; El-Serag HB
Gastroenterology; 2019 Feb; 156(3):809-811. PubMed ID: 30514636
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
